Loading company…
Y-Biologics researches and develops antibody drugs and cancer therapies.
Y-Biologics researches antibody drugs and therapeutics designed to reduce cancer cell growth. Its work includes YBL-006, an antibody immuno-oncology drug, and Alice, a technology that activates T-immune cells to kill cancer cells. The company is based in Daejeon, South Korea, and was founded in 2007. In December 2023, it raised KRW 13.5 billion in an IPO on the KOSDAQ.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in